23 Valent Pneumococcal Polysaccharide Vaccine (lot 1): All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112011), intramuscularly injected into the lateral deltoid muscle of the upper arm.
23 Valent Pneumococcal Polysaccharide Vaccine (lot 2): All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112012), intramuscularly injected into the lateral deltoid muscle of the upper arm.
23 Valent Pneumococcal Polysaccharide Vaccine (lot 3): All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112013), intramuscularly injected into the lateral deltoid muscle of the upper arm.
Study summary
The research objective is to evaluate lot-to-lot consistency and immune persistence of three commercial batches of 23 valent pneumococcal polysaccharide vaccine.
Eligibility
Sex
ALL
Min age
18 Years
Max age
59 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Healthy volunteers aged 18-59;
* Voluntarily participate and sign an informed consent form;
* Subjects are able to comply with the requirements of the clinical study protocol and complete the prescribed follow-up;
* Has not received pneumococcal vaccine or any other preventive products recently (has not received attenuated live vaccine within 14 days, has not received inactivated vaccine within 7 days);
* Underarm temperature ≤ 37.0 ℃;
* Female participants of childbearing age agree to take effective contraceptive measures within 3 months from the start of the study until the full vaccination period.
Exclusion Criteria:
* Subjects with a history or family history of progressive neurological disorders such as epilepsy, encephalopathy, and mental illness;
* Has a history of severe allergies to any drugs or vaccines in the past;
* Has a allergy history to any component of the experimental vaccine (the main components of the vaccine include type 23 pneumococcal polysaccharides, sodium chloride, sodium dihydrogen phosphate, and sodium dihydrogen phosphate);
* Suffering from severe cardiovascular diseases (heart disease, pulmonary heart disease, pulmonary edema, drug-resistant hypertension (systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 100mmHg)); drug-resistant diabetes;
* Subjects with a history of thrombocytopenia or other coagulation disorders that may cause contraindications for subcutaneous injection;
* Subjects with known immunological dysfunction or low levels, or HIV infection;
* Any situation leading to splenomegaly, splenectomy, or functional splenomegaly;
* Malignant tumors, active or treated tumors that have not been clearly cured, or are likely to recur during the study period;
* Anti tuberculosis prevention or treatment is under way;
* Subjects who are participating in or planning to participate in clinical trials of other drugs or vaccine clinical trials throughout the entire observation period;
* Women of childbearing age are in pregnancy (positive urine pregnancy test) or lactation period;
* Any situation that the researcher believes may affect the evaluation of the study.
Primary outcome measure(s)
Geometric mean concentration (GMC) levels — 30 days after immunization Geometric mean concentration (GMC) levels of 23 serotype specific IgG antibodies
Trial sites (1)
Facility
City
Region
Status
Sichuan Center for Disease Control and Prevention
Chengdu
Sichuan
More Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.